» Articles » PMID: 15085295

Advantages and Limitations of FDG PET in the Follow-up of Breast Cancer

Overview
Date 2004 Apr 16
PMID 15085295
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

18F-Fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) has been evaluated in breast cancer for the characterisation of primary tumours, lymph node staging and the follow-up of patients after surgery, chemotherapy and/or external radiotherapy. In contrast to both the low sensitivity and moderate specificity of FDG PET in the initial detection and characterisation of breast cancer and the low lesion-based sensitivity for lymph node staging, the results from use of FDG PET in re-staging breast cancer patients are very promising. A major advantage of FDG PET imaging compared with conventional imaging is that it screens the entire patient for local recurrence, lymph node metastases and distant metastases during a single whole-body examination using a single injection of activity, with a reported average sensitivity and specificity of 96% and 77%, respectively. In most studies the sensitivity of FDG PET is higher than that of a combination of conventional imaging methods. Limitations of FDG PET in the follow-up of breast cancer patients include the relatively low detection rate of bone metastases, especially in case of the sclerotic subtype, and the relatively high rate of false positive results. The rather low specificity of FDG PET can be improved/increased by utilising combined anatomical-molecular imaging techniques, such as a PET/CT tomograph. First results using PET/CT imaging in the follow-up of breast cancer patients demonstrate increased specificity compared with FDG PET alone. Both imaging modalities, however, offer to detect recurrent and metastatic breast cancer disease at an early stage and thus continue to demonstrate the efficacy of molecular imaging in patient management, despite the limited therapeutic options in recurrent and metastatic breast cancer.

Citing Articles

Head-to-head comparison of F-FDG and Ga-FAPI PET/CT in common gynecological malignancies.

Li T, Zhang J, Yan Y, Zhang Y, Pei W, Hua Q Cancer Imaging. 2025; 25(1):21.

PMID: 40022239 PMC: 11869701. DOI: 10.1186/s40644-025-00843-7.


FAP-targeted PET/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management.

Guo W, Xu W, Meng T, Fan C, Fu H, Pang Y Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39883140 DOI: 10.1007/s00259-025-07108-2.


Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine.

Shabsigh M, Solomon L Chem Biomed Imaging. 2024; 2(9):615-630.

PMID: 39474267 PMC: 11503725. DOI: 10.1021/cbmi.4c00030.


Imaging biomarkers between primary and metastatic tumors revealed by total-body positron emission tomography/computed tomography-based radiomics: a case series.

Li J, Qiu J, Cheng Z, Lu W Quant Imaging Med Surg. 2024; 14(6):4255-4262.

PMID: 38846317 PMC: 11151234. DOI: 10.21037/qims-24-21.


Applications of FAPI PET/CT in the diagnosis and treatment of breast and the most common gynecologic malignancies: a literature review.

Li T, Zhang J, Yan Y, Tan M, Chen Y Front Oncol. 2024; 14:1358070.

PMID: 38505595 PMC: 10949888. DOI: 10.3389/fonc.2024.1358070.


References
1.
Tack D, De Maertelaer V, Gevenois P . Dose reduction in multidetector CT using attenuation-based online tube current modulation. AJR Am J Roentgenol. 2003; 181(2):331-4. DOI: 10.2214/ajr.181.2.1810331. View

2.
Baslaim M, Bakheet S, Bakheet R, Ezzat A, El-Foudeh M, Tulbah A . 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg. 2003; 27(10):1099-104. DOI: 10.1007/s00268-003-6893-z. View

3.
Thompson C, Murthy K, Weinberg I, Mako F . Feasibility study for positron emission mammography. Med Phys. 1994; 21(4):529-38. DOI: 10.1118/1.597169. View

4.
Lind P, Gallowitsch H, Kogler D, Kresnik E, Mikosch P, Gomez I . Tc-99m-tetrofosmin scintimammography: a prospective study in primary breast lesions. Nuklearmedizin. 1996; 35(6):225-9. View

5.
von Schulthess G . Cost considerations regarding an integrated CT-PET system. Eur Radiol. 2000; 10 Suppl 3:S377-80. DOI: 10.1007/pl00014098. View